Detalhe da pesquisa
1.
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
Cancer
; 130(1): 41-50, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37658645
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439329
3.
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
Hematol Oncol
; 42(4): e3289, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38824453
4.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38818978
5.
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.
Ann Hematol
; 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38805036
6.
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.
Eur J Haematol
; 111(6): 922-929, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37747757
7.
Multicentric Castleman Disease and Concurrent Hematological Disorders: The Occurrence of Plasmacytoma and the Hypotheses Arising from Literature Review.
Acta Haematol
; 146(4): 331-337, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068478
8.
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.
Hematol Oncol
; 40(5): 987-998, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35794705
9.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638723
10.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608183
11.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716957
12.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica
; 106(4): 1079-1085, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107329
13.
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
Acta Haematol
; 2021 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34839282
14.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Cancer
; 125(5): 750-760, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561775
15.
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
Hematol Oncol
; 37(2): 117-128, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30192023
16.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Ann Hematol
; 98(2): 361-367, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30353388
17.
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Chemotherapy
; 64(2): 110-114, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31533095
18.
Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
Int J Mol Sci
; 20(21)2019 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31683978
19.
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3.
Int J Mol Sci
; 20(14)2019 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32565533
20.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Blood
; 127(9): 1102-8, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26729895